NYSEMKT: INFUInfusystem Holdings Inc Stock
$4.91-0.07 (-1.41%)
Updated Apr 17, 2025
INFU Price
$4.91
Fair Value Price
N/A
Market Cap
$103.16M
52 Week Low
$4.61
52 Week High
$9.97
P/E
44.64x
P/B
1.79x
P/S
1.33x
PEG
6.47x
Dividend Yield
N/A
Revenue
$134.86M
Earnings
$2.35M
Gross Margin
52.2%
Operating Margin
5.07%
Profit Margin
1.7%
Debt to Equity
0.8
Operating Cash Flow
$20M
Beta
0.86
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
INFU Overview
InfuSystem Holdings, Inc. engages in the provision of health care services. The company is headquartered in Madison Heights, Michigan and currently employs 238 full-time employees. The firm delivers local, field-based customer support and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Texas and Ontario, Canada. Its service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics for the treatment of a range of cancers, including colorectal cancer, pain management and other disease states. The company sells or rents new and pre-owned pole mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for oncology practices, as well as other alternate site settings, including home care and home infusion providers, skilled nursing facilities, pain centers and others.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INFU's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
INFU
Ranked#1 of 41
Ranked#1 of 41
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $90.89 | B | |
| $60.83 | B | |
| $198.71 | B |
Be the first to know about important INFU news, forecast changes, insider trades & much more!
INFU News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INFU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INFU ($4.91) is trading above its intrinsic value of $0.86, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INFU is poor value based on its earnings relative to its share price (44.64x), compared to the US market average (27.98x)
P/E vs Market Valuation
INFU is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more INFU due diligence checks available for Premium users.
Valuation
INFU price to earnings (PE)
For valuing profitable companies with steady earnings
Company
44.64x
Industry
40.39x
Market
27.98x
INFU is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
INFU is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
INFU price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.79x
Industry
3.55x
INFU is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INFU price to earnings growth (PEG)
For valuing profitable companies with growth potential
INFU is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
INFU's financial health
Profit margin
Revenue
$33.8M
Net Income
$933.0k
Profit Margin
2.8%
INFU's Earnings (EBIT) of $6.84M... subscribe to Premium to read more.
Interest Coverage Financials
INFU's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$103.6M
Liabilities
$46.1M
Debt to equity
0.8
INFU's short-term assets ($32.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INFU's short-term assets ($32.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INFU's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INFU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$7.9M
Investing
-$3.3M
Financing
-$4.5M
INFU's operating cash flow ($20.46M)... subscribe to Premium to read more.
Debt Coverage Financials
INFU vs Medical Stocks
Infusystem Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.